Metformin Synto

Metformin Hydrochloride, the active ingredient in Metformin Synto, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus, helping to improve overall glycaemic control and is indicated for long‑term management of the disease.

GNH USA supplies Metformin Synto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides batch‑tested product for global distribution.

Metformin Synto, a biguanide antidiabetic, is used to manage hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels.

Metformin Synto may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: reduced absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes. - Hypoglycaemia: uncommon when used alone, may occur with other glucose‑lowering agents. - Acute pancreatitis: very rare inflammatory condition of the pancreas.

Metformin Synto requires careful assessment of patient factors and monitoring to minimise risks. - Renal function: evaluate eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal, hepatic or cardiac impairment. - Alcohol consumption: limit intake as it may increase lactic acidosis risk. - Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant. - Drug interactions: review concomitant medications for agents that may affect metformin levels. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Synto can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Nitrates: combined use may heighten the chance of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Thiazide diuretics: can attenuate glucose‑lowering effect. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Digoxin: may require dose adjustment due to altered renal clearance. - Sulfonylureas: increased risk of hypoglycaemia when used together.